Skip to main
EYPT
EYPT logo

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EyePoint Pharmaceuticals (EYPT) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 50%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

EyePoint Pharmaceuticals is demonstrating significant investment in research and development, with R&D expenses rising to $132.9 million, indicating a commitment to advancing its innovative product pipeline, particularly the DURAVYU platform. Positive clinical data highlights the effectiveness of DURAVYU, with improved visual outcomes and anatomical control in treated patients, showcasing its potential superiority over existing treatments. The geographical diversification and strong revenue generation from the U.S. market position EyePoint Pharmaceuticals favorably within the ophthalmic pharmaceutical sector, contributing to a positive outlook for the company's stock.

Bears say

EyePoint Pharmaceuticals Inc. reported a significant net loss of $41.4 million in the fourth quarter of 2024, contributing to an overall net loss of $130.9 million for the year, which reflects a deterioration in financial performance compared to the previous year's loss of $70.8 million. There are concerns surrounding the regulatory approval process for EYP-1901, as potential delays or lack of alignment with regulatory requirements could hinder the product's progression, thereby impacting future revenue streams. These financial challenges and regulatory uncertainties collectively suggest a negative outlook for the company's stock.

EyePoint Pharmaceuticals (EYPT) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 50% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About EyePoint Pharmaceuticals (EYPT) Forecast

Analysts have given EyePoint Pharmaceuticals (EYPT) a Buy based on their latest research and market trends.

According to 14 analysts, EyePoint Pharmaceuticals (EYPT) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

EyePoint Pharmaceuticals (EYPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.